International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic dataDaniel A. Arber, Michael R. Savona, Attilio Orazi et al.|Blood|2022Cited by 2.7k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaMichael J. Keating, Hagop M. Kantarjian, Susan O’Brien et al.|Journal of Clinical Oncology|2005Cited by 951
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:Hagop M. Kantarjian, Elihu H. Estey, Susan O’Brien et al.|Cancer|2006Cited by 607
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Jing Ning et al.|Cancer Discovery|2018Cited by 570
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaGuillermo Garcia‐Manero, Jean‐Pierre J. Issa, Hagop M. Kantarjian et al.|Blood|2006Cited by 468